Sign in
Taking people in South KoreaNo phase

Studies real-world safety of ozanimod in people with ulcerative colitis

Observes safety of ozanimod in adults with moderate to severe ulcerative colitis.

Key facts

Who runs it
Bristol-Myers Squibb
Where
Seoul, South KoreaSee the site
Trial code
Registry title
A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea
Status
Recruiting
People taking part
3,000 people, planned
Started
19 Apr 2024
Expected to end
1 Apr 2028
Type of study
Observational
Treatments tested
  • Ozanimod
Record updated
22 August 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The study is looking for adults in Korea with moderate to severe active ulcerative colitis who will receive ozanimod as approved on its label. It checks how safe the drug is in everyday use.

Age
19 years or older
Sex
All sexes can join.
Disease stage
Moderate to severe active ulcerative colitis

Main reasons for not taking part

  • Prescribed ozanimod for a use that is not approved in Korea
  • Ozanimod is contraindicated according to the Korean prescribing information approved by the Ministry of Food and Drug Safety

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Adult participants 19 years of age or older
  • Participants who will receive ozanimod according to the approved label after enrollment
  • Participants who sign the informed consent form voluntarily

Who cannot take part

  • Participants for whom ozanimod is contraindicated as clarified in Korean prescribing information approved by Ministry of Food and Drug Safety
  • Participants who are prescribed ozanimod for therapeutic indications not approved in Korea

Where in South Korea

  • Bristol-Myers Squibb YHSeoul, South KoreaContact: Hyunho KimTaking people

About the trial

What the trial wants to find out

The purpose of this observational study is to assess the real-world safety of ozanimod in Korean participants with moderate to severe active ulcerative colitis.

The group in the trial

  • Participants with moderate to severe active ulcerative colitis treated with ozanimod

    Treatment: Ozanimod

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Post-Marketing Surveillance (PMS) Study on Zeposia® (Ozanimod) Use Among Moderate to Severe Active Ulcerative Colitis Patients in Korea
Plain-language title
Studies real-world safety of ozanimod in people with ulcerative colitisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
22 August 2024